Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer’s Olodaterol Will Have To Pass LABA Hurdles At January Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehringer Ingelheim’s long acting beta-adrenergic agonist for chronic obstructive pulmonary disease will have to overcome LABA class issues in asthma at an advisory committee in January. The drug is up first for single-agent approval, but it is meant to be half of a combination therapy with the blockbuster treatment Spiriva.

Advertisement

Related Content

Boehringer’s Olodaterol Gains Advisory Committee Support, But May See Indication Clarified
BI’s Olodaterol Wants Novel Exercise Claims In COPD
Boehringer Ingelheim’s Me-Too Petition Against Generic Spiriva
Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose
FDA Supersizes Its Order For LABA Safety Studies
COPD Drug Dose Selection May Face Greater Scrutiny In Arcapta’s Wake
Safety Meta-Analysis Trumped By Long, Large Trial At Spiriva Advisory Panel

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel